Primary study · included by 1 review
Salivary Gland Toxicity after Radioiodine Therapy for Thyroid Cancer
Hyer 2007 · Hyer S., Kong A., Pratt B., et al. · Clinical Oncology · 2007
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · within 2 months after RIT | Prevalence 0.60 [0.28, 0.85] | 3 studies · 1502 participants | GRADE not reported |
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · between 2 and 6 months after RIT | Prevalence 0.37 [0.28, 0.47] | 4 studies · 392 participants | GRADE not reported |
1 including review in total.